The FDA declined to approve Summit's lung cancer drug after the trial missed a key survival goal. That is the binary risk in the equity, and no approval leaves the story trading on a missed endpoint,
FDA declined approval after the drug missed a key survival goal.
SMMT
$11.82
-16.47%
What changed
FDA declined approval after the drug missed a key survival goal.
Why it matters
FDA declined approval after the drug missed a key survival goal. — impact context not separately stored; see What changed.